FDA Requires Labeling Changes For Transplant Drugs
Federal regulators are requiring the makers of certain immunosuppressant drugs used to protect against organ transplant rejection to update their labeling to reflect that patients are at increased risk for opportunistic...To view the full article, register now.
Already a subscriber? Click here to view full article